Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05399004
Other study ID # 19-007376
Secondary ID NCI-2021-13603
Status Active, not recruiting
Phase
First received
Last updated
Start date September 3, 2019
Est. completion date September 2024

Study information

Verified date February 2024
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study evaluates the general physical, emotional, and sexual function in women undergoing a radical cystectomy for bladder cancer. A radical cystectomy is a surgical procedure that involves the removal of the bladder, uterus, ovaries, fallopian tubes, and part of the vagina. This may affect sexual function in women. This study seeks to understand how radical cystectomy alters sexual function and well-being, and what factors may affect this change.


Description:

PRIMARY OBJECTIVES: I. To characterize pre-operative sexual function and interest in sexual activity of women undergoing radical cystectomy. II. To identify patient understanding and expectations as they relate to sexual dysfunction after radical cystectomy. III. To describe pre-operative importance in sexual function recovery after radical cystectomy. IV. Quantify the changes in sexual function within the year following radical cystectomy in women. V. Explore the effects of age, baseline sexual function, general quality of life, parity, menopausal status, hormone replacement therapy (topical versus [vs.] oral), general and cancer related quality of life, chemotherapy (neoadjuvant vs. adjuvant), treatment-related complications and performance status on sexual function outcomes. VI. Explore the effects of robotic vs. open approach, extracorporeal vs. intracorporal approach, organ-sparing (ovaries, uterus, cervix, anterior vaginal wall), type of vaginal closure (vertical vs. horizontal), nerve sparing, urinary diversion type (ileal conduit vs. neobladder vs. continent cutaneous diversion) on sexual function outcomes. VII. Quantify the changes in sexual activity interest within the year following radical cystectomy. OUTLINE: Patients complete surveys over 15-20 minutes at baseline and at 3, 6, and 12 months.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 34
Est. completion date September 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult women greater than 18 years of age - A diagnosis of bladder cancer - Planned to undergo a radical cystectomy - Willing and able to complete survey questionnaires Exclusion Criteria: - Inability to provide informed consent - Non-English speaking - Life expectancy less than 2 years

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Survey Administration
Complete surveys

Locations

Country Name City State
United States Albany Medical Center Albany New York
United States University of Michigan Comprehensive Cancer Center Ann Arbor Michigan
United States Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland
United States Brigham and Women's Hospital Boston Massachusetts
United States UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina
United States M D Anderson Cancer Center Houston Texas
United States University of Iowa/Holden Comprehensive Cancer Center Iowa City Iowa
United States Louisiana State University Lafayette Louisiana
United States Vanderbilt University/Ingram Cancer Center Nashville Tennessee
United States University of Pennsylvania/Abramson Cancer Center Philadelphia Pennsylvania
United States Mayo Clinic in Rochester Rochester Minnesota
United States Huntsman Cancer Institute/University of Utah Salt Lake City Utah
United States University of Washington Medical Center - Montlake Seattle Washington
United States Sibley Memorial Hospital Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Physical function Assessed using the PROMIS - 29 Profile v2.1. Contrasts within the linear mixed effects model will compare changes in subdomain score between different time points. From baseline to 3, 6, and 12 months
Other Fatigue Assessed using the PROMIS - 29 Profile v2.1. Contrasts within the linear mixed effects model will compare changes in subdomain score between different time points. From baseline to 3, 6, and 12 months
Other Pain interference Assessed using the PROMIS - 29 Profile v2.1. Contrasts within the linear mixed effects model will compare changes in subdomain score between different time points. From baseline to 3, 6, and 12 months
Other Depressive symptoms Assessed using the PROMIS - 29 Profile v2.1. Contrasts within the linear mixed effects model will compare changes in subdomain score between different time points. From baseline to 3, 6, and 12 months
Other Anxiety Assessed using the PROMIS - 29 Profile v2.1. Contrasts within the linear mixed effects model will compare changes in subdomain score between different time points. From baseline to 3, 6, and 12 months
Other Ability to participate in social roles and activities Assessed using the PROMIS - 29 Profile v2.1. Contrasts within the linear mixed effects model will compare changes in subdomain score between different time points. From baseline to 3, 6, and 12 months
Other Sleep disturbances Assessed using the PROMIS - 29 Profile v2.1. Contrasts within the linear mixed effects model will compare changes in subdomain score between different time points. From baseline to 3, 6, and 12 months
Other Preoperative expectations/importance of sexual function recovery Will use a linear mixed effects model of sexual function scores measured post-baseline through 12 months, adjusted for baseline sexual function score to evaluate if preoperative expectation/importance of sexual function recovery is associated with outcomes over time. Baseline
Primary Preoperative sexual function Assessed using the Patient Reported Outcomes Measurement Information System (PROMIS) Brief Profile Sexual Function and Satisfaction version 2 (v2.0). Will utilize descriptive statistics to report preoperative sexual function. Frequencies and percentages will be reported for categorical variables and mean (standard deviation) or median (interquartile range) for continuous variables. Baseline
Primary Interest in sexual activity Will descriptively summarize the within-patient changes using the PROMIS Brief Profile Sexual Function and Satisfaction v2.0. Contrasts within the linear mixed effects model will compare changes in subdomain score between different time points. From baseline to 3, 6, and 12 months
Primary Lubrication Will descriptively summarize the within-patient changes using the PROMIS Brief Profile Sexual Function and Satisfaction v2.0. Contrasts within the linear mixed effects model will compare changes in subdomain score between different time points. From baseline to 3, 6, and 12 months
Primary Vaginal discomfort Will descriptively summarize the within-patient changes using the PROMIS Brief Profile Sexual Function and Satisfaction v2.0. Contrasts within the linear mixed effects model will compare changes in subdomain score between different time points. From baseline to 3, 6, and 12 months
Primary Satisfaction with sex life Will descriptively summarize the within-patient changes using the PROMIS Brief Profile Sexual Function and Satisfaction v2.0. Contrasts within the linear mixed effects model will compare changes in subdomain score between different time points. From baseline to 3, 6, and 12 months
Secondary Labial discomfort Will descriptively summarize the within-patient changes using the PROMIS Brief Profile Sexual Function and Satisfaction v2.0. Contrasts within the linear mixed effects model will compare changes in subdomain score between different time points. From baseline to 3, 6, and 12 months
Secondary Clitoral discomfort Will descriptively summarize the within-patient changes using the PROMIS Brief Profile Sexual Function and Satisfaction v2.0. Contrasts within the linear mixed effects model will compare changes in subdomain score between different time points. From baseline to 3, 6, and 12 months
Secondary Orgasm ability Will descriptively summarize the within-patient changes using the PROMIS Brief Profile Sexual Function and Satisfaction v2.0. Contrasts within the linear mixed effects model will compare changes in subdomain score between different time points. From baseline to 3, 6, and 12 months
Secondary Orgasm pleasure Will descriptively summarize the within-patient changes using the PROMIS Brief Profile Sexual Function and Satisfaction v2.0. Contrasts within the linear mixed effects model will compare changes in subdomain score between different time points. From baseline to 3, 6, and 12 months
Secondary Change in sexual function scores Will use a linear mixed effects model of 12-month sexual function scores adjusting for baseline function to evaluate independent variables of interest related to the surgical procedure: age, robotic/open approach, pelvic organ sparing and diversion type. Variables of interest will be analyzed separately. In the analysis of robotic vs. open approach, the model will include terms for time (after surgery: 3, 6, and 12 months, using a discrete time formulation), approach (robotic=1, open=0), and approach by time interaction. Contrasts of the interaction and main effects will allow estimation of whether outcomes at 12 months differ by approach. From baseline to 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting NCT03824691 - hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study" Phase 2
Recruiting NCT04502095 - Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy Phase 4
Completed NCT03125226 - TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer N/A
Withdrawn NCT05564416 - Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial Phase 2
Terminated NCT02169284 - Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery Phase 2
Recruiting NCT05519878 - Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers N/A
Active, not recruiting NCT02439060 - PUBMIC (Prophylactic Use of Biologic Mesh in Ileal Conduit) N/A
Recruiting NCT04410302 - Patient-Derived Xenografts to Reduce Cancer Health Disparities
Withdrawn NCT04054752 - Vaccine Response With NT-I7 Phase 1
Terminated NCT03549650 - Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms Phase 2
Completed NCT00469066 - Cone Beam CT Scanning in Lung and Bladder Cancer. N/A
Active, not recruiting NCT03757949 - Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery Phase 3
Completed NCT03064308 - The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery N/A
Active, not recruiting NCT02432963 - Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Phase 1
Active, not recruiting NCT02408406 - PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers N/A
Recruiting NCT06109857 - Bladder Bank (a Prospective Banking Study)
Terminated NCT02145390 - Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy N/A
Terminated NCT01245660 - A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy Phase 0
Withdrawn NCT02438852 - Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer Phase 3

External Links